v3.25.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 110,614 $ 37,797
Short-term marketable securities 20,241 50,553
Receivables from collaborative arrangements 15,353 18,440
Receivables from milestones and royalty assets   50,000
Other prepaid and current assets 4,056 4,277
Total current assets 150,264 161,067
Property and equipment, net 7,028 7,418
Operating lease assets 27,430 28,354
Future contingent milestone and royalty assets 144,200 144,200
Restricted cash 836 836
Other assets 13,824 12,286
Total assets 343,582 354,161
Current liabilities:    
Accounts payable 2,408 2,242
Accrued personnel-related expenses 5,386 7,019
Accrued clinical and development expenses 2,457 1,058
Accrued general and administrative expenses 2,520 2,987
Operating lease liabilities 10,807 10,712
Income tax payable 5,853 5,853
Other accrued liabilities 2,071 2,214
Total current liabilities 31,502 32,085
Long-term operating lease liabilities 37,349 39,108
Future royalty payment contingency 30,977 30,334
Unrecognized tax benefits 76,484 75,199
Other long-term liabilities 1,287 1,890
Commitments and contingencies (Note 10)
Shareholders' Equity    
Preferred shares, $0.00001 par value per share: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 50,001 and 49,471 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 1  
Additional paid-in capital 1,145,083 1,141,060
Accumulated other comprehensive income (loss)   7
Accumulated deficit (979,101) (965,522)
Total shareholders' equity 165,983 175,545
Total liabilities and shareholders' equity $ 343,582 $ 354,161